Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Mesothelioma, Malignant × Interleukin-2 × Clear all
NCT05086692 2025-07-09

ABILITY-1

Medicenna Therapeutics, Inc.

Phase 1/2 Recruiting
115 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Basal Cell, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Skin Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms